Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
ESTRADIOL HEMIHYDRATE
B & S Healthcare
25 Microgram
Vaginal Tablets
2011-10-21
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Vagifem 25 micrograms Vaginal Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE INGREDIENT: One vaginal tablet contains Estradiol hemihydrate equivalent to estradiol 25 micrograms. EXCIPIENTS: lactose For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Vaginal Tablet _Product imported from Italy:_ White, biconvex film-coated vaginal tablet marked 'NOVO 279' on one side and inset in a disposable applicator 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of atrophic vaginitis due to estrogen deficiency. The experience of treating women older than 65 years is limited. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION DOSAGE The usual dosage is one tablet (containing 25 micrograms estradiol) daily for 2 weeks followed by a maintenance dose of one tablet twice a week. Treatment should be limited to as short a period as possible. ADMINISTRATION For intravaginal administration only, using the supplied applicator. Each applicator with insert tablet is intended for single use only. Treatment may be started on any convenient day. If a dose is forgotten, it should be taken as soon as the patient remembers. A double dose should be avoided. For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (_see section 4.4, Special warnings and precautions for use_) should be used. Vagifem may be used in women with or without an intact uterus. During treatment, especially during the first two weeks, minimal absorption may be seen but as plasma oestradiol levels after the first two weeks usually do not exceed postmenopausal levels the addition of a progestogen is not recommended. IRISH MEDICINES BOARD ________________________________ Read the complete document